To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
$5,300
BUY NOW
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cell-Based Assays Market size was valued at USD 17.6 billion in 2022 and is poised to grow from USD 19.14 billion in 2023 to USD 37.44 billion by 2031, growing at a CAGR of 8.75% during the forecast period (2024-2031).

The competitive landscape of the cell-based assays market is marked by intense innovation, strategic collaborations, and a focus on cutting-edge technology to meet the expanding demands of drug discovery, toxicology studies, and biomedical research. Industry leaders like Thermo Fisher Scientific, Merck KGaA, and PerkinElmer have established their dominance through a combination of advanced assay development, extensive product portfolios, and reach. 'Thermo Fisher Scientific, Inc. (United States)', 'Promega Corporation (United States)', 'Merck KGaA (Germany)', 'PerkinElmer, Inc. (United States)', 'Danaher Corporation (United States)', 'Cell Signaling Technology, Inc. (United States)', 'Bio-Rad Laboratories, Inc. (United States)', 'Agilent Technologies, Inc. (United States)', 'GE Healthcare (United Kingdom)', 'Lonza Group Ltd. (Switzerland)'

The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders fuels the demand for advanced cell-based assays for disease modeling and drug testing.

3D Cell Culture Advancements: The shift towards more physiologically relevant 3D cell culture models is gaining traction, allowing better recapitulation of in vivo conditions and enabling improved drug screening and toxicity assessment.

North America stands as the dominant force globally, commanding a substantial market share, and this is attributed to its well-established healthcare sector and the widespread adoption of cell-based assays. The United States, in particular, showcases a robust healthcare landscape and a remarkable proclivity towards utilizing cell-based assays. Notably, the escalating prevalence of chronic diseases such as cancer, osteoarthritis, and diabetes within the United States fuels an augmented demand for cell-based assays, especially in the realm of pioneering drug discoveries. This phenomenon significantly contributes to the market's expansion, acting as a pivotal growth catalyst.

Feedback From Our Clients

Global Cell-Based Assays Market

Product ID: SQMIG35H2154

$5,300
BUY NOW